2-(4-chlorobutyl)-3,4-dihydro-6-ethynylisoquinolin-1(2H)-one | 1309955-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 2-(4-chlorobutyl)-3,4-dihydro-6-ethynylisoquinolin-1(2H)-one
• CAS: 1309955-30-3
• 化学式: C₁₅H₁₆ClNO
• 分子量: 261.751
• InChiKey: ISMBUERBHMNEBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.69
• 重原子数：
  18.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  20.31
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  1-(2-甲氧苯基)哌嗪 、 2-(4-chlorobutyl)-3,4-dihydro-6-ethynylisoquinolin-1(2H)-one 在 potassium carbonate 、 potassium iodide 作用下， 以 4-甲基-2-戊酮 为溶剂， 反应 49.0h， 以47%的产率得到USC-O401
  参考文献：
  名称：

  Aromatic ring functionalization of benzolactam derivatives: New potent dopamine D3 receptor ligands

  摘要：

  Since the discovery of the dopamine D-3 receptor, an intensive effort has been directed toward the development of potent and selective ligands in order to elucidate the function and potential therapeutic advantages of targeting D-3 receptors. As a part of our efforts, a novel series of substituted benzolactams derivatives was synthesized mostly through palladium-catalyzed reactions. Their affinities on D-1-D-4 receptors were evaluated and the data led us to highly potent D-3 ligands, some of them highly selective for D-3 receptor, compared to the related dopamine receptor subtypes. Functional D-3 activity assays of the most relevant compounds have been carried out revealing antagonist as well as partial agonist activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.083
• 作为产物：
  描述：

  6-溴-3,4-二氢-2H-异喹啉-1-酮 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 16.0h， 生成 2-(4-chlorobutyl)-3,4-dihydro-6-ethynylisoquinolin-1(2H)-one
  参考文献：
  名称：

  Aromatic ring functionalization of benzolactam derivatives: New potent dopamine D3 receptor ligands

  摘要：

  Since the discovery of the dopamine D-3 receptor, an intensive effort has been directed toward the development of potent and selective ligands in order to elucidate the function and potential therapeutic advantages of targeting D-3 receptors. As a part of our efforts, a novel series of substituted benzolactams derivatives was synthesized mostly through palladium-catalyzed reactions. Their affinities on D-1-D-4 receptors were evaluated and the data led us to highly potent D-3 ligands, some of them highly selective for D-3 receptor, compared to the related dopamine receptor subtypes. Functional D-3 activity assays of the most relevant compounds have been carried out revealing antagonist as well as partial agonist activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.083